Seed Team
Nessan Bermingham, Ph.D.
Founder & Executive Chairman

Nessan Bermingham is a founder and Chairman of the Board of Directors of Korro Bio, Inc. He is a serial biotech entrepreneur and investor who has founded several companies, including Korro Bio, Triplet Therapeutics, and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company.”. He has nearly two decades of experience in life sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets.

As a venture partner at Atlas Venture and managing partner at Omega Funds, Dr. Bermingham successfully invested in and managed multiple investments across the United States and Europe. Currently, he also serves as the Chairman of the Board of Directors of F-star and Akrevia Therapeutics. Previously, Dr. Bermingham served as the President and CEO of Intellia Therapeutics from inception until December 2017.

Dr. Bermingham was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner.

This is some text inside of a div block.
Jean-François Formela, M.D.
Founder, Director & Partner at Atlas Venture

Jean-François Formela is a partner and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He is chairman of IFM Therapeutics and Triplet Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Korro Bio, Kyn Therapeutics, Spero Therapeutics (NASDAQ: SPRO), and Translate Bio (NASDAQ: TBIO).

Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), Arteaus Therapeutics (acquired by Eli Lilly), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), and NxStage (NASDAQ: NXTM, acquired by Fresenius Medical). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis).

Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough where he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. He began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.

Jean-François is a member of the MGH Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.

This is some text inside of a div block.
Stuart Milstein, Ph.D.
VP, Platform Biology

Stuart Milstein was previously at Alnylam Pharmaceuticals where he established and led the RNAi Lead Development group which was responsible for the lead development and optimization for all clinical candidates in the Alnylam pipeline. He also initiated work on delivery of siRNAs to the central nervous system and led the CNS delivery platform.

Prior to joining Alnylam, Stu was a Research Fellow in the department of Genetics at Harvard Medical School and Dana Farber Cancer Institute and received his Ph.D. through the Genetics program from Cold Spring Harbor Laboratory and Stony Brook University.

This is some text inside of a div block.
Scientific Advisory Board
Josh Rosenthal, Ph.D.
Founder & Prof MBL, Adar Bio

Joshua C. Rosenthal is a neurobiologist who studies how marine organisms adapt to the physical environment. He advises Korro from the Marine Biological Laboratory (MBL), and prior to that, came from the University of Puerto Rico, Medical Sciences Campus, where he was a Professor in the Institute of Neurobiology.

Rosenthal’s research focuses on developing new, genetically tractable marine model organisms and understanding how they are affected by a changing environment. His expertise is in RNA editing, a natural process by which RNA transcripts from expressed genes in a cell are edited, thereby potentially altering the proteins that the cell will produce.

Rosenthal first came to the MBL in the 1990s with William F. Gilly, his doctoral advisor at Stanford University, to conduct research on the squid giant axon. He subsequently did postdoctoral research at the University of California, Los Angeles, with Francisco Bezanilla (now a Professor at the University of Chicago), with whom he also collaborated at the MBL.

This is some text inside of a div block.
Andrew Fraley, Ph.D.
Founder & SVP, Technology

Andrew Fraley, a founder of Korro Bio, serves as SVP of Technology to the company. Andrew brings over 20 years of experience in the field of nucleic acid technologies and therapeutics. A scientist and entrepreneur at heart, he has founded biotech companies including Korro Bio, Triplet Therapeutics and Trucode Gene Repair.

Prior to Korro, Andrew was a founding executive team member and served as SVP of Translational Sciences for Trucode Gene Repair, an in vivo gene editing company, leading the company's scientific strategy and operations. He has also served in key senior leadership roles within the biotech community, including Moderna Therapeutics, enabling the development of modified messenger RNA, and Ensemble Therapeutics, providing leadership for platform development & macrocyclic discovery.

Dr. Fraley has authored and reviewed scientific publications and is listed as an inventor on patents in areas including nucleic acid therapeutics, oligonucleotide delivery, and macrocyclic drug discovery. He has served as a Boston University Kindle Mentor and has consulted for government organizations, venture firms and biotech startups. He holds a B.A. from DePauw University, earned his Ph.D. in Bio-organic Chemistry at Boston College, and was a Chateaubriand Postdoctoral Research Fellow at the Université de Louis Pasteur.

This is some text inside of a div block.
Nessan Bermingham, Ph.D.
Founder & Executive Chairman

Nessan Bermingham is a founder and Chairman of the Board of Directors of Korro Bio, Inc. He is a serial biotech entrepreneur and investor who has founded several companies, including Korro Bio, Triplet Therapeutics, and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company.”. He has nearly two decades of experience in life sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets.

As a venture partner at Atlas Venture and managing partner at Omega Funds, Dr. Bermingham successfully invested in and managed multiple investments across the United States and Europe. Currently, he also serves as the Chairman of the Board of Directors of F-star and Akrevia Therapeutics. Previously, Dr. Bermingham served as the President and CEO of Intellia Therapeutics from inception until December 2017.

Dr. Bermingham was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner.

This is some text inside of a div block.
Jean-François Formela, M.D.
Founder, Director & Partner at Atlas Venture

Jean-François Formela is a partner and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He is chairman of IFM Therapeutics and Triplet Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Korro Bio, Kyn Therapeutics, Spero Therapeutics (NASDAQ: SPRO), and Translate Bio (NASDAQ: TBIO).

Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), Arteaus Therapeutics (acquired by Eli Lilly), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), and NxStage (NASDAQ: NXTM, acquired by Fresenius Medical). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis).

Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough where he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. He began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.

Jean-François is a member of the MGH Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.

This is some text inside of a div block.
leadership, founders, & board member BIOS
Josh Rosenthal, Ph.D.
Founder & Prof MBL, Adar Bio

Joshua C. Rosenthal is a neurobiologist who studies how marine organisms adapt to the physical environment. He advises Korro from the Marine Biological Laboratory (MBL), and prior to that, came from the University of Puerto Rico, Medical Sciences Campus, where he was a Professor in the Institute of Neurobiology.

Rosenthal’s research focuses on developing new, genetically tractable marine model organisms and understanding how they are affected by a changing environment. His expertise is in RNA editing, a natural process by which RNA transcripts from expressed genes in a cell are edited, thereby potentially altering the proteins that the cell will produce.

Rosenthal first came to the MBL in the 1990s with William F. Gilly, his doctoral advisor at Stanford University, to conduct research on the squid giant axon. He subsequently did postdoctoral research at the University of California, Los Angeles, with Francisco Bezanilla (now a Professor at the University of Chicago), with whom he also collaborated at the MBL.

Andrew Fraley, Ph.D.
Founder & SVP, Technology

Andrew Fraley, a founder of Korro Bio, serves as SVP of Technology to the company. Andrew brings over 20 years of experience in the field of nucleic acid technologies and therapeutics. A scientist and entrepreneur at heart, he has founded biotech companies including Korro Bio, Triplet Therapeutics and Trucode Gene Repair.

Prior to Korro, Andrew was a founding executive team member and served as SVP of Translational Sciences for Trucode Gene Repair, an in vivo gene editing company, leading the company's scientific strategy and operations. He has also served in key senior leadership roles within the biotech community, including Moderna Therapeutics, enabling the development of modified messenger RNA, and Ensemble Therapeutics, providing leadership for platform development & macrocyclic discovery.

Dr. Fraley has authored and reviewed scientific publications and is listed as an inventor on patents in areas including nucleic acid therapeutics, oligonucleotide delivery, and macrocyclic drug discovery. He has served as a Boston University Kindle Mentor and has consulted for government organizations, venture firms and biotech startups. He holds a B.A. from DePauw University, earned his Ph.D. in Bio-organic Chemistry at Boston College, and was a Chateaubriand Postdoctoral Research Fellow at the Université de Louis Pasteur.

Nessan Bermingham, Ph.D.
Founder & Executive Chairman

Nessan Bermingham is a founder and Chairman of the Board of Directors of Korro Bio, Inc. He is a serial biotech entrepreneur and investor who has founded several companies, including Korro Bio, Triplet Therapeutics, and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company.”. He has nearly two decades of experience in life sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets.

As a venture partner at Atlas Venture and managing partner at Omega Funds, Dr. Bermingham successfully invested in and managed multiple investments across the United States and Europe. Currently, he also serves as the Chairman of the Board of Directors of F-star and Akrevia Therapeutics. Previously, Dr. Bermingham served as the President and CEO of Intellia Therapeutics from inception until December 2017.

Dr. Bermingham was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner.

Jean-François Formela, M.D.
Founder, Director & Partner at Atlas Venture

Jean-François Formela is a partner and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He is chairman of IFM Therapeutics and Triplet Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Korro Bio, Kyn Therapeutics, Spero Therapeutics (NASDAQ: SPRO), and Translate Bio (NASDAQ: TBIO).

Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), Arteaus Therapeutics (acquired by Eli Lilly), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), and NxStage (NASDAQ: NXTM, acquired by Fresenius Medical). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis).

Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough where he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. He began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.

Jean-François is a member of the MGH Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.

Ali Behbahani, M.D.
Director & General Partner at NEA

Ali joined NEA in 2007 and is currently a General Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products.

He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University.

Ali concurrently earned his M.D. degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University.

Ommer Chohan
Director & CFO at Atlas Venture

Ommer Chohan serves as Atlas Venture’s chief financial officer overseeing the firm’s financial, legal, and operations functions. Prior to joining Atlas, Ommer was Chief Financial Officer and Chief Operating Officer at Summerhill Venture Partners.

At Summerhill Ommer was responsible for the finance, IT, and administrative functions in addition to providing financial and legal support to the investment team.  

Ommer received his BA-Honours, Specialist in Management from the University of Toronto, his MBA from the Johnson School at Cornell University, and earned his CPA (Ontario) while at PricewaterhouseCoopers.

Anna L. Barry, Ph.D., J.D.
Chief Legal Officer

Dr. Barry is a seasoned biotech executive with more than 20 years of senior leadership and legal experience in the life sciences industry.  Dr. Barry currently serves as Chief Legal Officer at Korro Bio, Inc. She was most recently Senior Vice President, General Counsel and Corporate Secretary at Jounce Therapeutics, Inc. (NASDAQ: JNCE), where she was responsible for all aspects of its legal department, negotiated strategic partnerships and executed its initial public offering.

Prior to Jounce Therapeutics, Dr. Barry served as a Senior Director of IP at Five Prime Therapeutics and Senior Patent Counsel at Genentech.  Prior to Genentech, Dr. Barry was an attorney at Heller Ehrman LLP, where her practice focused on counseling life sciences and biotechnology companies.  Dr. Barry received her J.D. from Vanderbilt University, an M.S. and Ph.D. in Biophysical Chemistry from Yale University and earned a B.S. in Chemistry from Georgia Institute of Technology.

Matthew Jarpe, Ph.D.
VP, Target Biology

Matthew Jarpe serves as Vice President of Target Biology for Korro Bio. Previously, Matt was Vice President of Research and Development at Regenacy Pharmaceuticals, and Associate Vice President of Biology at Acetylon Pharmaceuticals where he led the development of highly selective inhibitors for HDAC6 as well as HDAC1 and 2 in several non-oncology disease targets.

Prior to joining Acetylon, Matt worked at Biogen as a Senior Scientist and at Surface Logix as an Associate Director of Biology. He received his Ph.D. from Johns Hopkins and completed his postdoctoral training at National Jewish Medical Center.

Stuart Milstein, Ph.D.
VP, Platform Biology

Stuart Milstein was previously at Alnylam Pharmaceuticals where he established and led the RNAi Lead Development group which was responsible for the lead development and optimization for all clinical candidates in the Alnylam pipeline. He also initiated work on delivery of siRNAs to the central nervous system and led the CNS delivery platform.

Prior to joining Alnylam, Stu was a Research Fellow in the department of Genetics at Harvard Medical School and Dana Farber Cancer Institute and received his Ph.D. through the Genetics program from Cold Spring Harbor Laboratory and Stony Brook University.

Contact Us
Get in touch for investment, partnership, or career inquiries; or to learn more about our technology and pipeline.
LOADING CAPTCHA...
Thank you!
Your submission has been received.
We will reply as soon as possible!
Oops! Something went wrong while submitting the form.
KORRO BIO, INC.
400 Technology Square, ​10th Floor
Cambridge, MA  02139
LOCATE US ON GOOGLE MAPS